Literature DB >> 8121739

Clinical consequences and treatment of primary immunodeficiency syndromes characterized by functional T and B lymphocyte anomalies (combined immune deficiency).

F Berthet1, F Le Deist, A M Duliege, C Griscelli, A Fischer.   

Abstract

OBJECTIVE: To review the clinical presentation and outcome of patients with an unusual primary T + B lymphocyte immunodeficiency syndrome, characterized by the presence of T lymphocytes with no detectable gross phenotypic anomaly, but which are not activated in vitro or in vivo in response to antigens, although they do respond to mitogens.
METHODS: A retrospective analysis of clinical and immunological data recorded in 25 cases. Acquired immunodeficiencies and known primary T cell immunodeficiency syndromes (severe combined immunodeficiency syndrome, Di-George syndrome, Wiskott-Aldrich syndrome, cartilage hair hypoplasia, Omenn's syndrome, ataxia telangiectasia, defective expression of major histocompatibility complex class II molecules, and defective expression of the CD3/T cell receptor complex) were excluded.
RESULTS: The patients had severe and particularly protracted infections, mainly of the respiratory tract and gut. Severe viral infections, generally due to herpes viruses, occurred in nearly two-thirds of the patients, with a median follow-up of 54 months. Autoimmune manifestations are frequent (60%), targetting mainly marrow-derived cells, and were characterized by a tendency to relapse and by a dependence on immunosuppressive therapy. Allergic manifestations were also frequent (48% of cases). Eight of the 19 patients who had not undergone bone marrow transplantation died. All but one of the 11 survivors had moderate to severe sequelae. Bone marrow transplantation seemed to be the treatment of choice, because four of six recipients of HLA-identical (n = 2) or nonidentical (n = 4) marrow are alive and the immune deficiency has been corrected.
CONCLUSION: Early recognition of these life-threatening syndromes may improve the chances of cure. Despite common clinical manifestations and prognosis, these functional immunodeficiencies appear heterogeneous regarding inheritance pattern and at least existence of a B cell immunodeficiency.

Entities:  

Mesh:

Year:  1994        PMID: 8121739

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  7 in total

Review 1.  Primary T-lymphocyte immunodeficiencies.

Authors:  A Fischer
Journal:  Clin Rev Allergy Immunol       Date:  2001-02       Impact factor: 8.667

Review 2.  Stem cell transplantation for immunodeficiency.

Authors:  A Fischer; E Haddad; N Jabado; J L Casanova; S Blanche; F Le Deist; M Cavazzana-Calvo
Journal:  Springer Semin Immunopathol       Date:  1998

Review 3.  Enterocolitis in infantile common variable immunodeficiency. A case report and review of the literature.

Authors:  H A John; K E Sullivan; C Smith; A E Mulberg
Journal:  Dig Dis Sci       Date:  1996-03       Impact factor: 3.199

4.  Severe combined immunodeficiency (SCID): from the detection of a new mutation to preimplantation genetic diagnosis.

Authors:  Reut Tomashov-Matar; Galia Biran; Irina Lagovsky; Neomi Kotler; Anat Stein; Benjamin Fisch; Onit Sapir; Mordechai Shohat
Journal:  J Assist Reprod Genet       Date:  2012-04-22       Impact factor: 3.412

Review 5.  A syndrome of primary combined immunodeficiency with microcephaly, cerebellar hypoplasia, growth failure and progressive pancytopenia.

Authors:  F Berthet; R Caduff; U B Schaad; H Roten; P Tuchschmid; E Boltshauser; R A Seger
Journal:  Eur J Pediatr       Date:  1994-05       Impact factor: 3.183

Review 6.  Immunodeficiency and genetic conditions that cause arthritis in childhood.

Authors:  Pierre Quartier; Anne-Marie Prieur
Journal:  Curr Rheumatol Rep       Date:  2002-12       Impact factor: 4.686

7.  Treatment of experimental autoimmune uveoretinitis with different natural compounds.

Authors:  Man Li; Xiaoming Chen; Juanjuan Liu; Dongmei Wang; Lu Gan; Xin Lv; Yu Qiao
Journal:  Mol Med Rep       Date:  2016-04-08       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.